Pixelgen has closed a Series A financing of approximately USD 7.3 million.
The round was led by new investor Industrifonden, Sweden’s venture capital fund, and Navigare Ventures, an investor in Pixelgen’s Seed round. Proceeds from the financing will support the commercial expansion of Pixelgen’s recently launched spatial proteomics tool for analyzing cell surface proteins on single cells to transform drug discovery and basic science.
“Pixelgen has made great progress since we emerged from stealth less than a year ago. Last month we shipped our first product to advance drug development and research in immunology, and we’ve expanded our team with top talent,” says Pixelgen CEO Simon Fredriksson. “As we enter this next phase of growth, we are grateful and honored to have the support and expertise of Industrifonden and Navigare Ventures and look forward to their contributions.”
Patrik Sobocki will join Pixelgen’s board of directors
In conjunction with the financing, Industrifonden Senior Investment Director Patrik Sobocki, will join Pixelgen’s board of directors. Sobocki brings decades of experience in healthcare, technology, and entrepreneurship to the board, in addition to his background in international research and development and commercial leadership roles in global pharmaceutical companies.
“We are extremely excited to back Pixelgen. Its team of strong serial entrepreneurs with unicorn outcomes and a unique technology foundation combining advanced molecular research and computational innovation fit perfectly with Industrifonden’s deep tech investment strategy and expertise in computational biology. We are honored to support Simon and his team to become a category leader within spatial proteomics in the coming decade,” says Sobocki.
Photo: Pixelgen Technologies